Innovations in Cancer Nanotheranostics

A special issue of Nanomaterials (ISSN 2079-4991). This special issue belongs to the section "Biology and Medicines".

Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 338

Special Issue Editor


E-Mail Website
Guest Editor
Department of Radiology, The University of Chicago, Chicago, IL, USA
Interests: nanomaterials; metamaterials; theranostics; plasmonics; X-ray-activated photodynamic therapy; nanodosimetry; nanoautoradiography; diffuse optical tomography; diffusing wave emission tomography

Special Issue Information

Dear Colleagues,

Nanotheranostics—biocompatible nanomaterials that serve both diagnostic and therapeutic roles—hold great promise in the diagnoses, treatment, and prevention of disease. Their intrinsically small dimensions, large surface area to volume ratios, and readily modified surface chemistries/physics afford enormous flexibility in platform design and function. Comprised of organic, inorganic, or hybrid organic-inorganic materials, nanotheranostics come in a wide variety of topologies with domains optimized for therapeutic/reporter conveyance and functionalized for pathology-targeting and enhanced biocompatibility/biodistribution. As such these platforms are uniquely qualified to address many of the current limitations of conventional drug delivery, like inefficient targeting and systemic toxicity, while simultaneously providing new capabilities, like real-time monitoring disease status and precision control of therapeutic release.

This Special Issue focuses on the latest innovations in nanotheranostics that are specifically designed for the staging, diagnosis, treatment, and prevention of cancer. Potential areas of interest for this Issue include, but are not limited to:

  • Novel functionalizations and applications (e.g., X-ray photodynamic therapy, in vivo gene editing and immunotherapy, precision medicine);
  • Novel materials and synthesis (e.g., metal-organic frameworks, organic/inorganic hybrids, in vivo self-assembling platforms, smart materials, bio-metamaterials);
  • Novel targeting moieties and strategies (e.g., tumor microenvironment targeting, evasion of immune surveillance, immune activation);
  • Novel therapeutic release/activation mechanisms (smart/autonomous, externally controlled/monitored, programmable);
  • Enhancements in nanoplatform biodistribution, bioelimination, and biocompatibility;
  • Enhancements in physiological barrier penetration (e.g., blood-brain barrier, mucosal barrier, tumor stroma, intratumoral pressure gradient);
  • Advances in multimodal-targeted therapy and image guidance.

Dr. Jeffrey S. Souris
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nanomaterials is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • theranostics
  • nanotheranostics
  • nanomaterials
  • nanoparticle
  • cancer
  • tumor
  • contrast agent
  • drug delivery
  • controlled release
  • multimodality

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop